Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Fresenius Kabi Launches Subcutaneous Formulation of its Tocilizumab Biosimilar in US

Jul 2, 2024

Fresenius Kabi has launched its subcutaneous formulation of Tyenne® (tocilizumab-aazg), biosimilar to Roche’s Actemra® (tocilizumab), in the United States.  This new formulation provides patients with primary immunodeficiency diseases a convenient alternative to intravenous administration. 

Both subcutaneous and intravenous forms of Tyenne were FDA approved on 5 March 2024. Fresenius launched the IV formulation of Tyenne in the US in April 2024.  Fresenius Kabi launched Tyenne in Europe as the first to market biosimilar in November 2023 in both IV and SC formulations.